Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21607886 | 0.84 | ALOX5AP (0.52) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL23791421 | 0.81 | GPR119 (0.55) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL21607904 | 0.81 | ALOX5AP (0.53) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL20281797 | 0.81 | ALOX5AP (0.53) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL8601284 | 0.81 | GPR119 (0.53) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL30785509 | 0.80 | RBP4 (0.54) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL27158623 | 0.80 | RBP4 (0.54) | ALOX5APFEN1GPR119KDM4EPKM | |
| SCHEMBL18973366 | 0.79 | GPR119 (0.56) | GPR119KDM4EPKMUSP30FAAH | |
| SCHEMBL1155733 | 0.79 | KDM4E (0.52) | GPR119KDM4EPKMUSP30JAK2 | |
| SCHEMBL30785499 | 0.79 | RBP4 (0.53) | ALOX5APFEN1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ALOX5AP 1427/4885FEN1 333/4885GPR119 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.